Oncorus, Inc.
NASDAQ: ONCR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert CIRA
- Employees
- 64
- Headquarters
- Cambridge, United States
- IPO year
- 2020
- Website
- https://www.oncorus.com
Loading ONCR…
Loading profile data…Frequently asked questions about ONCR
What does Oncorus, Inc. (ONCR) do?
Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform. This candidate, administered directly into tumors, i...
Where does ONCR trade?
Oncorus, Inc. (ONCR) trades on the NASDAQ Global Market.
What sector is ONCR in?
Oncorus, Inc. (ONCR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Oncorus, Inc.?
Craig R. Jalbert CIRA is the chief executive officer of Oncorus, Inc. (ONCR).
Where is Oncorus, Inc. headquartered?
Oncorus, Inc. is headquartered in United States.
Does ONCR pay a dividend?
Yes — Oncorus, Inc. (ONCR) paid a trailing twelve-month dividend of USD 0.14 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ONCR go public?
Oncorus, Inc. (ONCR) completed its initial public offering in 2020.